You are here

Article Text

Article menu
Download PDFPDF
Oncology
Complete response to chemotherapy in a 6-year survivor of metastatic pancreatic cancer
  1. Cynthia E Burke1,
  2. Nina L Eng2,
  3. Nelson S Yee3 and
  4. June S Peng4,5
  1. 1Penn State College of Medicine, Hershey, PA, USA
  2. 2Department of Surgery, Penn State College of Medicine, Hershey, PA, USA
  3. 3Division of Hematology and Oncology, Department of Medicine, Penn State College of Medicine, Hershey, PA, USA
  4. 4Divsion of Surgical Oncology, Department of Surgery, Penn State College of Medicine, Hershey, PA, USA
  5. 5Division of Surgical Oncology, Department of Surgery, UCSF, San Francisco, CA, USA
  1. Correspondence to Dr June S Peng; june.peng{at}ucsf.edu

Abstract

A woman in her 40s underwent evaluation for abdominal pain, jaundice and acholic stools and was diagnosed with metastatic pancreatic head adenocarcinoma. She was enrolled in a clinical trial investigating the benefits of ibrutinib with nab-paclitaxel and gemcitabine, and subsequently received modified FOLFIRINOX. Over the course of 6 years on chemotherapy, she experienced complete regression of the pancreatic and liver lesions, as well as normalisation of her tumour markers. She has been off chemotherapy for 6 months with no evidence of disease and normal tumour markers. Despite advances in chemotherapy and surgical options, metastatic pancreatic adenocarcinoma continues to carry a grim prognosis. This case report demonstrates a rare case of a long-term survivor of unresectable metastatic pancreatic adenocarcinoma treated with chemotherapy alone.

  • pancreatic cancer
  • surgical oncology

https://doi.org/10.1136/bcr-2024-261008

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms and critical revision for important intellectual content: CEB, NLE, NSY, JSP. The following authors gave final approval of the manuscript: CEB, NLE, NSY, JSP.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.